Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the best performers on Monday.

Dyne Therapeutics jumped by 9.47 percent on Monday to finish at $22.20 apiece as investors cheered the encouraging results from its ongoing clinical trial to test the efficacy of therapy candidate, zeleciment rostudirsen, for individuals with Duchenne muscular dystrophy (DMD).

In an update on the same day, Dyne Therapeutics, Inc. (NASDAQ:DYN) said that the drug candidate met its primary endpoint, demonstrating a 5.46 percent increase in muscle-content adjusted dystrophin levels alongside functional improvements across multiple clinical endpoints.

“With its high level of dystrophin expression, favorable safety profile, convenient monthly dosing regimen, and functional improvement as assessed by six prespecified clinical measures, z-rostudirsen has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” said Dyne Therapeutics, Inc. (NASDAQ:DYN) President and CEO John Cox.

Notably, the therapy was considered generally safe and tolerable, with the commonly reported adverse effects being only fever and headache.

The trial enrolled 32 ambulant and non-ambulant males with DMD aged 4 to 16 and had mutations amenable to a method called exon 51 skipping.

The company said it is on track to submit an accelerated approval in the second quarter of 2026, positioning itself to launch the said therapy in the first quarter of 2026.